Targeting Tumor-Associated Macrophages in Cancer

Hargadon, 2018, Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors, Int. Immunopharmacol., 62, 29, 10.1016/j.intimp.2018.06.001 Newick, 2017, CAR T cell therapy for solid tumors, Annu. Rev. Med., 68, 139, 10.1146/annurev-med-062315-120245 Ribas, 2018, Cancer immunotherapy using checkpoint blockade, Science, 359, 1350, 10.1126/science.aar4060 Wei, 2018, Fundamental mechanisms of immune checkpoint blockade therapy, Cancer Discov., 8, 1069, 10.1158/2159-8290.CD-18-0367 Vajaitu, 2018, The central role of inflammation associated with checkpoint inhibitor treatments, J Immunol. Res., 2018, 10.1155/2018/4625472 Kaneda, 2016, PI3Kgamma is a molecular switch that controls immune suppression, Nature, 539, 437, 10.1038/nature19834 De Henau, 2016, Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells, Nature, 539, 443, 10.1038/nature20554 Mills, 2016, A breakthrough: macrophage-directed cancer immunotherapy, Cancer Res., 76, 513, 10.1158/0008-5472.CAN-15-1737 Ruffell, 2015, Macrophages and therapeutic resistance in cancer, Cancer Cell, 27, 462, 10.1016/j.ccell.2015.02.015 Cassetta, 2018, Targeting macrophages: therapeutic approaches in cancer, Nat. Rev. Drug Discov., 10.1038/nrd.2018.169 Schmid, 2011, Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression, Cancer Cell, 19, 715, 10.1016/j.ccr.2011.04.016 Kaneda, 2016, Macrophage PI3Kgamma drives pancreatic ductal adenocarcinoma progression, Cancer Discov., 6, 870, 10.1158/2159-8290.CD-15-1346 Quail, 2016, The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas, Science, 352, aad3018, 10.1126/science.aad3018 Gao, 2016, CCL2/EGF positive feedback loop between cancer cells and macrophages promotes cell migration and invasion in head and neck squamous cell carcinoma, Oncotarget, 7, 87037, 10.18632/oncotarget.13523 Pyonteck, 2013, CSF-1R inhibition alters macrophage polarization and blocks glioma progression, Nat. Med., 19, 1264, 10.1038/nm.3337 Nywening, 2016, Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial, Lancet Oncol., 17, 651, 10.1016/S1470-2045(16)00078-4 Schmid, 2011, Combined blockade of integrin-alpha4beta1 plus cytokines SDF-1alpha or IL-1beta potently inhibits tumor inflammation and growth, Cancer Res., 71, 6965, 10.1158/0008-5472.CAN-11-0588 Schmid, 2013, PI3-kinase gamma promotes Rap1a-mediated activation of myeloid cell integrin alpha4beta1, leading to tumor inflammation and growth, PLoS One, 8, 10.1371/journal.pone.0060226 Cai, 2009, Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo, Neoplasia, 11, 228, 10.1593/neo.81282 Lesokhin, 2012, Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment, Cancer Res., 72, 876, 10.1158/0008-5472.CAN-11-1792 Lu, 2006, Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion, Prostate, 66, 1311, 10.1002/pros.20464 Lu, 2009, Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone, J. Biol. Chem., 284, 29087, 10.1074/jbc.M109.035899 Ueno, 2000, Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer, Clin. Cancer Res., 6, 3282 Bonapace, 2014, Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis, Nature, 515, 130, 10.1038/nature13862 Connolly, 2016, Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes, Oncotarget, 7, 86522, 10.18632/oncotarget.13287 Karin, 2018, The role of CCR5 in directing the mobilization and biological function of CD11b(+)Gr1(+)Ly6C(low) polymorphonuclear myeloid cells in cancer, Cancer Immunol. Immunother., 67, 1949, 10.1007/s00262-018-2245-6 Li, 2017, Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma, Gut, 66, 157, 10.1136/gutjnl-2015-310514 Bruchard, 2013, Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth, Nat. Med., 19, 57, 10.1038/nm.2999 Isambert, 2018, Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study, Oncoimmunology, 7, 10.1080/2162402X.2018.1474319 Gerhardt, 2015, Monocyte trafficking across the vessel wall, Cardiovasc. Res., 107, 321, 10.1093/cvr/cvv147 Schmid, 2018, Integrin CD11b activation drives anti-tumor innate immunity, Nat. Commun., 9, 5379, 10.1038/s41467-018-07387-4 Gunderson, 2016, Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer, Cancer Discov, 6, 270, 10.1158/2159-8290.CD-15-0827 Franklin, 2014, The cellular and molecular origin of tumor-associated macrophages, Science, 344, 921, 10.1126/science.1252510 Gomez Perdiguero, 2015, Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors, Nature, 518, 547, 10.1038/nature13989 Davies, 2015, Tissue-resident macrophages: then and now, Immunology, 144, 541, 10.1111/imm.12451 Guerriero, 2018, Macrophages: the road less traveled, changing anticancer therapy, Trends Mol. Med., 24, 472, 10.1016/j.molmed.2018.03.006 Schulz, 2012, A lineage of myeloid cells independent of Myb and hematopoietic stem cells, Science, 336, 86, 10.1126/science.1219179 Yona, 2013, Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis, Immunity, 38, 79, 10.1016/j.immuni.2012.12.001 Stremmel, 2018, Yolk sac macrophage progenitors traffic to the embryo during defined stages of development, Nat. Commun., 9, 75, 10.1038/s41467-017-02492-2 Zhu, 2017, Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression, Immunity, 47, 597, 10.1016/j.immuni.2017.08.018 Hashimoto, 2013, Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes, Immunity, 38, 792, 10.1016/j.immuni.2013.04.004 Bowman, 2016, Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies, Cell Rep., 17, 2445, 10.1016/j.celrep.2016.10.052 Gautier, 2012, Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages, Nat. Immunol., 13, 1118, 10.1038/ni.2419 Mass, 2016, Specification of tissue-resident macrophages during organogenesis, Science, 353, 10.1126/science.aaf4238 Atanasov, 2018, TIE2-expressing monocytes and M2-polarized macrophages impact survival and correlate with angiogenesis in adenocarcinoma of the pancreas, Oncotarget, 9, 29715, 10.18632/oncotarget.25690 Gartrell, 2018, Quantitative analysis of immune infiltrates in primary melanoma, Cancer Immunol. Res., 6, 481, 10.1158/2326-6066.CIR-17-0360 Zhang, 2018, Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients, J. Surg. Res., 222, 93, 10.1016/j.jss.2017.09.035 Sorensen, 2018, Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype, Neuropathol. Appl. Neurobiol., 44, 185, 10.1111/nan.12428 Hu, 2016, Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma, J. Exp. Clin. Cancer Res., 35, 12, 10.1186/s13046-015-0281-z Wang, 2015, High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type, Ann. Hematol., 94, 1535, 10.1007/s00277-015-2401-4 Tiainen, 2015, High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer, Histopathology, 66, 873, 10.1111/his.12607 Pedersen, 2014, High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma, Histopathology, 65, 490, 10.1111/his.12407 Zhang, 2013, High-infiltration of tumor-associated macrophages predicts unfavorable clinical outcome for node-negative breast cancer, PLoS One, 8 Foubert, 2017, PI3Kgamma activates integrin alpha4 and promotes immune suppressive myeloid cell polarization during tumor progression, Cancer Immunol. Res., 5, 957, 10.1158/2326-6066.CIR-17-0143 Guerriero, 2017, Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages, Nature, 543, 428, 10.1038/nature21409 Ofengeim, 2013, Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death, Nat. Rev. Mol. Cell Biol., 14, 727, 10.1038/nrm3683 Wang, 2018, RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer, Cancer Cell, 34, 757, 10.1016/j.ccell.2018.10.006 Bromberg, 1998, Stat3 activation is required for cellular transformation by v-src, Mol. Cell. Biol., 18, 2553, 10.1128/MCB.18.5.2553 Bromberg, 1999, Stat3 as an oncogene, Cell, 98, 295, 10.1016/S0092-8674(00)81959-5 Pathria, 2015, Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice, Oncoimmunology, 4, 10.1080/2162402X.2014.998529 Hoves, 2018, Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity, J. Exp. Med., 215, 859, 10.1084/jem.20171440 Lum, 2006, Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha, Immunology, 118, 261, 10.1111/j.1365-2567.2006.02366.x Lum, 2006, In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages, J. Leukoc. Biol., 79, 1181, 10.1189/jlb.0405191 Wiehagen, 2017, Combination of CD40 agonism and CSF-1R blockade reconditions tumor-associated macrophages and drives potent antitumor immunity, Cancer Immunol. Res., 5, 1109, 10.1158/2326-6066.CIR-17-0258 Nowak, 2015, A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma, Ann. Oncol., 26, 2483, 10.1093/annonc/mdv387 Medler, 2018, Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy, Cancer Cell, 34, 561, 10.1016/j.ccell.2018.09.003 Affara, 2014, B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas, Cancer Cell, 25, 809, 10.1016/j.ccr.2014.04.026 Zha, 2017, Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade, Oncoimmunology, 6, 10.1080/2162402X.2017.1349587 DeNardo, 2011, Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy, Cancer Discov., 1, 54, 10.1158/2159-8274.CD-10-0028 Shiao, 2015, TH2-polarized CD4(+) T cells and macrophages limit efficacy of radiotherapy, Cancer Immunol Res, 3, 518, 10.1158/2326-6066.CIR-14-0232 Quail, 2017, Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies, Clin. Cancer Res., 23, 876, 10.1158/1078-0432.CCR-16-0133 Yan, 2017, Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas, Oncogene, 36, 6049, 10.1038/onc.2017.261 Ries, 2014, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy, Cancer Cell, 25, 846, 10.1016/j.ccr.2014.05.016 Paulus, 2006, Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts, Cancer Res., 66, 4349, 10.1158/0008-5472.CAN-05-3523 Pyonteck, 2012, Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development, Oncogene, 31, 1459, 10.1038/onc.2011.337 Beffinger, 2018, CSF1R-dependent myeloid cells are required for NKmediated control of metastasis, JCI Insight, 3, 10.1172/jci.insight.97792 Jaiswal, 2009, CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis, Cell, 138, 271, 10.1016/j.cell.2009.05.046 Zhao, 2016, CD47 Promotes tumor invasion and metastasis in non-small cell lung cancer, Sci. Rep., 6, 29719, 10.1038/srep29719 Tseng, 2013, Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response, Proc. Natl. Acad. Sci. U. S. A., 110, 11103, 10.1073/pnas.1305569110 Okazawa, 2005, Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system, J. Immunol., 174, 2004, 10.4049/jimmunol.174.4.2004 Barclay, 2014, The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target, Annu. Rev. Immunol., 32, 25, 10.1146/annurev-immunol-032713-120142 Petrova, 2017, TTI-621 (SIRPalphaFc): A CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding, Clin. Cancer Res., 23, 1068, 10.1158/1078-0432.CCR-16-1700 Gholamin, 2017, Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors, Sci. Transl. Med., 9, 10.1126/scitranslmed.aaf2968 Covarrubias, 2015, Control of macrophage metabolism and activation by mTOR and Akt signaling, Semin. Immunol., 27, 286, 10.1016/j.smim.2015.08.001 Huang, 2016, Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation, Immunity, 45, 817, 10.1016/j.immuni.2016.09.016 Porta, 2018, Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy, FEBS J., 285, 717, 10.1111/febs.14288 Noy, 2014, Tumor-associated macrophages: from mechanisms to therapy, Immunity, 41, 49, 10.1016/j.immuni.2014.06.010 Buck, 2017, Metabolic instruction of immunity, Cell, 169, 570, 10.1016/j.cell.2017.04.004 Geeraerts, 2017, Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity, Front. Immunol., 8, 289, 10.3389/fimmu.2017.00289 Colegio, 2014, Functional polarization of tumour-associated macrophages by tumour-derived lactic acid, Nature, 513, 559, 10.1038/nature13490 Bohn, 2018, Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages, Nat. Immunol., 19, 1319, 10.1038/s41590-018-0226-8 Kuchuk, 2018, pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma, Oncoimmunology, 7, 10.1080/2162402X.2018.1445452 Carmona-Fontaine, 2017, Metabolic origins of spatial organization in the tumor microenvironment, Proc. Natl. Acad. Sci. U. S. A., 114, 2934, 10.1073/pnas.1700600114 Geiger, 2016, L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity, Cell, 167, 829, 10.1016/j.cell.2016.09.031 Thomas, 2014, “Of mice and men”: arginine metabolism in macrophages, Front. Immunol., 5, 479, 10.3389/fimmu.2014.00479